TY - JOUR
T1 - Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes
AU - Guadagnino, Vincenzo
AU - Trotta, Maria Paola
AU - Montesano, Franco
AU - Babudieri, Sergio
AU - Caroleo, Benedetto
AU - Armignacco, Orlando
AU - Carioti, Jessica
AU - Maio, Giuseppe
AU - Monarca, Roberto
AU - Antinori, Andrea
PY - 2007/3
Y1 - 2007/3
N2 - Aim: To evaluate the effect of a multi-disciplinary standardized management model on the efficacy of pegylated (Peg)-interferon α-2b plus ribavirin treatment of chronic hepatitis C in drug addicts undergoing substitutive or antagonist therapy. Design: Observational prospective multi-centre study. Setting: Six clinical infectious disease centres in collaboration with 11 drug dependency units (DDU) in five Italian regions. Participants: Intravenous drug users affected by chronic hepatitis C engaged in detoxification programmes. Methods: Application of a multi-disciplinary standardized management model for HCV treatment involving DDU operators, psychologists or psychiatrists and infectious disease specialists. Measurements: Very early, early, end-of-treatment and sustained virological response to Peg-interferon α-2b plus ribavirin. Findings: Fifty-three subjects were studied [43.4% with hepatitis C virus (HCV) genotypes 1 or 4]. Intent-to-treat analysis showed an end-of-treatment virological response in 58.5% of patients (39.1% genotypes 1 or 4; 73.4% genotype 3) and a sustained virological response in 54.7% (34.8% genotypes 1 or 4; 70.0% genotype 3). There were 19 (35.8%) dropouts and three (5.7%) non-responders: one genotype 1 and two genotype 4. Two (3.8%) patients relapsed: genotypes 1 and 3. On-treatment analysis showed negative HCV-RNA in 40 (93.1%) of 43 subjects who completed the first 12 treatment weeks and in 35 who completed the first 24 treatment weeks. All subjects with an end-of-treatment response, except one with genotype 3 infection, had a sustained response. Conclusions: Our data show that antiviral treatment in the context of a multi-disciplinary standardized management model helps many HCV-positive drug addicts achieve a good virological response.
AB - Aim: To evaluate the effect of a multi-disciplinary standardized management model on the efficacy of pegylated (Peg)-interferon α-2b plus ribavirin treatment of chronic hepatitis C in drug addicts undergoing substitutive or antagonist therapy. Design: Observational prospective multi-centre study. Setting: Six clinical infectious disease centres in collaboration with 11 drug dependency units (DDU) in five Italian regions. Participants: Intravenous drug users affected by chronic hepatitis C engaged in detoxification programmes. Methods: Application of a multi-disciplinary standardized management model for HCV treatment involving DDU operators, psychologists or psychiatrists and infectious disease specialists. Measurements: Very early, early, end-of-treatment and sustained virological response to Peg-interferon α-2b plus ribavirin. Findings: Fifty-three subjects were studied [43.4% with hepatitis C virus (HCV) genotypes 1 or 4]. Intent-to-treat analysis showed an end-of-treatment virological response in 58.5% of patients (39.1% genotypes 1 or 4; 73.4% genotype 3) and a sustained virological response in 54.7% (34.8% genotypes 1 or 4; 70.0% genotype 3). There were 19 (35.8%) dropouts and three (5.7%) non-responders: one genotype 1 and two genotype 4. Two (3.8%) patients relapsed: genotypes 1 and 3. On-treatment analysis showed negative HCV-RNA in 40 (93.1%) of 43 subjects who completed the first 12 treatment weeks and in 35 who completed the first 24 treatment weeks. All subjects with an end-of-treatment response, except one with genotype 3 infection, had a sustained response. Conclusions: Our data show that antiviral treatment in the context of a multi-disciplinary standardized management model helps many HCV-positive drug addicts achieve a good virological response.
KW - HCV infection
KW - Intravenous drug use
KW - Management of hepatitis C
KW - Peg interferon
UR - http://www.scopus.com/inward/record.url?scp=33846937792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846937792&partnerID=8YFLogxK
U2 - 10.1111/j.1360-0443.2006.01698.x
DO - 10.1111/j.1360-0443.2006.01698.x
M3 - Article
C2 - 17298650
AN - SCOPUS:33846937792
VL - 102
SP - 423
EP - 431
JO - Addiction
JF - Addiction
SN - 0965-2140
IS - 3
ER -